Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

• David A. Wohl ,

  * E-mail: david_wohl@med.unc.edu

  Affiliation AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Laveeza Bhatti,

  Affiliation AIDS Healthcare Foundation, Beverly Hills, California, United States of America

  ⨯
• Catherine B. Small,

  Affiliation New York Medical College, Valhalla, New York, United States of America

  ⨯
• Howard Edelstein,

  Affiliation Alameda County Medical Center, Oakland, California, United States of America

  ⨯
• Henry H. Zhao,

  Affiliation GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• David A. Margolis,

  Affiliation GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Edwin DeJesus,

  Affiliation Orlando Immunology Center, Orlando, Florida, United States of America

  ⨯
• Winkler G. Weinberg,

  Affiliation Kaiser Foundation Health Plan of Georgia, Inc, Atlanta, Georgia, United States of America

  ⨯
• Lisa L. Ross,

  Affiliation ViiV Healthcare, Research Triangle Park, North Carolina, United States of America

  ⨯
• Mark S. Shaefer

  Affiliation ViiV Healthcare, Research Triangle Park, North Carolina, United States of America

  ⨯